Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Roche (SIX: ROP) sales rise 7% as pipeline hopes meet a near-record valuation
Roche delivered 7% constant-currency Q3 sales growth and maintained 2026 guidance as newer medicines offset patent erosion. With ROP touching a 52-week high and key medicines still awaiting regulatory decisions, pipeline conversion is becoming the next valuation test.
Zymeworks (ZYME) reports 64.5% ovarian cancer response rate for ZW191 as lower dose strengthens case
Zymeworks has reported encouraging Phase 1 results for its folate receptor alpha-targeting antibody-drug conjugate ZW191, including responses in ovarian tumors with low receptor expression and a more favorable safety profile at the lower tested dose.
CSL (ASX: CSL) names new CEO. Can 5% profit growth sustain its rally?
CSL shares have recovered sharply from their June lows as investors anticipate an earnings turnaround. The appointment of Deborah Waterhouse brings fresh leadership, but flat revenue guidance and persistent weakness at CSL Vifor leave an important question about how much recovery is already reflected in the share price.
F2G and Shionogi move closer to commercializing novel oral antifungal after pivotal trial results
Shionogi shares gain as olorofim's Phase 3 success advances its F2G partnership. Explore the $480M deal, FDA plans and market potential.
Roivant Sciences targets new uveitis market as brepocitinib delivers major clinical breakthrough
Roivant Sciences stock rises after brepocitinib's double Phase 3 uveitis success. Explore its FDA plans, cash strength and growth potential.
UCB shares surge as Bimzelx turns a mid-teens outlook into 20%-plus growth
UCB has upgraded 2026 revenue growth to the low twenties and adjusted EBITDA growth to the low-to-mid forties as Bimzelx demand and pricing outperform expectations in the United States.
Moderna (MRNA) falls 18% despite melanoma win: Can an $81bn valuation hold?
Moderna shares plunged 17.57% despite positive Phase 3 melanoma data from its personalised mRNA cancer therapy developed with Merck. With an approximately $81 billion market valuation, continued operating losses and a commercial opportunity extending well beyond melanoma, the central question is how much future oncology success investors have already priced in.
Stablepharma begins pivotal trial of fridge-free vaccine stable for 24 months at 30°C
Stablepharma has started a 160-participant Phase 2b trial of its thermostable tetanus-diphtheria vaccine, advancing a technology that could reduce dependence on refrigeration while opening commercial opportunities in vaccine distribution and temperature-sensitive medicines.
Aptar’s most profitable business has a new leader. Can Virginie Maes restart margin expansion?
Virginie Maes will take over Aptar Pharma after Gael Touya’s elevation to group CEO, inheriting a business with strong growth franchises but softer margins and a broader push from packaging into drug development services.
Odyssey Therapeutics targets major inflammatory bowel disease opportunity with oral OD-001
Odyssey Therapeutics stock rises on OD-001 ulcerative colitis results. Explore its $433M cash position, clinical trials and growth prospects.